Cliff Asness's SNDX Position Overview
Cliff Asness (via Aqr Capital Management LLC) currently holds 980,314 shares of Syndax Pharmaceuticals, Inc. (SNDX) worth $22.9 M, representing 0.01% of the portfolio. First purchased in 2017-Q3, this long-term strategic position has been held for 28 quarters.
Based on 13F filings, Cliff Asness has maintained a strategic position in SNDX, demonstrating sustained confidence in this investment. Largest addition occurred in Q4 2025, adding 367,898 shares. Largest reduction occurred in Q2 2025, reducing 146,867 shares.
Analysis based on 13F filings available since 2013 Q2
Cliff Asness's Syndax Pharmaceuticals (SNDX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Syndax Pharmaceuticals (SNDX) Trades by Cliff Asness
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +54,340 | Add 5.87% | 980,314 | $23.36 |
| Q4 2025 | +367,898 | Add 65.92% | 925,974 | $21.01 |
| Q3 2025 | +327,499 | Add 142.03% | 558,076 | $15.38 |
| Q2 2025 | -146,867 | Reduce 38.91% | 230,577 | $9.36 |
| Q1 2025 | +312,231 | Add 478.79% | 377,444 | $12.28 |
| Q4 2024 | +39,794 | Add 156.55% | 65,213 | $13.22 |
| Q3 2024 | -1,854 | Reduce 6.80% | 25,419 | $19.25 |
| Q2 2024 | -25,943 | Reduce 48.75% | 27,273 | $20.53 |
| Q1 2024 | +17,314 | Add 48.23% | 53,216 | $23.80 |
| Q4 2023 | +11,330 | Add 46.11% | 35,902 | $21.61 |
| Q3 2023 | +3,034 | Add 14.09% | 24,572 | $14.52 |
| Q2 2023 | -1,690 | Reduce 7.28% | 21,538 | $20.93 |
| Q1 2023 | -1,947 | Reduce 7.73% | 23,228 | $21.12 |
| Q4 2022 | +3,246 | Add 14.80% | 25,175 | $25.45 |
| Q3 2022 | -13,429 | Reduce 37.98% | 21,929 | $24.03 |
| Q2 2022 | +11,607 | Add 48.87% | 35,358 | $19.23 |
| Q1 2022 | +23,751 | New Buy | 23,751 | $17.39 |
| Q2 2021 | -18,680 | Sold Out | 0 | $0.00 |
| Q1 2021 | -11,283 | Reduce 37.66% | 18,680 | $22.38 |
| Q4 2020 | -12,972 | Reduce 30.21% | 29,963 | $22.23 |
| Q3 2020 | -1,873 | Reduce 4.18% | 42,935 | $14.77 |
| Q2 2020 | +34,079 | Add 317.63% | 44,808 | $14.82 |
| Q1 2020 | +10,729 | New Buy | 10,729 | $11.00 |
| Q2 2019 | -14,117 | Sold Out | 0 | $0.00 |
| Q1 2019 | +14,117 | New Buy | 14,117 | $5.24 |
| Q1 2018 | -26,068 | Sold Out | 0 | $0.00 |
| Q4 2017 | -7,121 | Reduce 21.46% | 26,068 | $8.75 |
| Q3 2017 | +33,189 | New Buy | 33,189 | $11.69 |
Cliff Asness's Syndax Pharmaceuticals Investment FAQs
Cliff Asness first purchased Syndax Pharmaceuticals, Inc. (SNDX) in Q3 2017, acquiring 33,189 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Cliff Asness has held Syndax Pharmaceuticals, Inc. (SNDX) for 28 quarters since Q3 2017.
Cliff Asness's largest addition to Syndax Pharmaceuticals, Inc. (SNDX) was in Q4 2025, adding 925,974 shares worth $19.45 M.
According to the latest 13F filing for Q1 2026, Cliff Asness's firm, Aqr Capital Management LLC, owns 980,314 shares of Syndax Pharmaceuticals, Inc. (SNDX), valued at approximately $22.9 M.
As of the Q1 2026 filing, Syndax Pharmaceuticals, Inc. (SNDX) represents approximately 0.01% of Cliff Asness's publicly disclosed stock portfolio, making it one of their key holdings.
Cliff Asness's peak holding in Syndax Pharmaceuticals, Inc. (SNDX) was 980,314 shares, as reported at the end of Q1 2026.